JPRN-UMIN000047934
Completed
未知
Safety and Efficacy of a Single 48 mm Everolimus-Eluting Stent in Percutaneous Coronary Intervention for Diffuse Coronary Lesions: A propensity score analysis - Safety and Efficacy of a Single 48 mm Everolimus-Eluting Stent in Percutaneous Coronary Intervention for Diffuse Coronary Lesions: A propensity score analysis
agano Municipal Hospita0 sites130 target enrollmentJune 3, 2022
ConditionsCoronary Artery Disease
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Coronary Artery Disease
- Sponsor
- agano Municipal Hospita
- Enrollment
- 130
- Status
- Completed
- Last Updated
- 2 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- Not provided
Exclusion Criteria
- •Multiple stents without overlap
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
EVINEC: Safety and Tolerability of Everolimus as second-line treatment in poorly differentiated neuroendocrine carcinoma / neuroendocrine carcinoma G3 according to WHO 2010 and neuroendocrine tumor G3 - an investigtor initiated Phase II study.• Poorly differentiated neuroendocrine carcinoma, neuroendocrine carcinoma G3 (NEC G3 according to WHO 2010) with primary tumor outside lung• Well to moderately differentiated neuroendocrine carcinoma (NET G1/G2) that switched to G3 (confirmed by histology)• Neuroendocrine tumor G3 (NET G3)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-004550-28-DEAIO-Studien-gGmbH
Completed
Not Applicable
Assessment of efficy and safety of everolimus in Japanese patients with mRCCrenal cell carcinomaJPRN-UMIN000009620Tokyo Afinitor Clinical Trial Group200
Recruiting
Phase 2
Efficacy of 0.05%topical everolimus in the treatment of adenoma sebaceum in tuberous sclerosisadenoma sebaceumTCTR20180820002Dermatology division, Department of internal medicine, King Chulalongkorn Memorial Hospital15
Active, not recruiting
Phase 1
Activity and safety of Everolimus in combination with octreotide LAR and Metformin in patients with advanced pancreatic well-differentiated Neuroendocrine Tumors (pWDNETs): a Phase II, open, monocentric, prospective study.advanced/ or not resectable well differnciated pancreatic neuroendocrin tumorMedDRA version: 16.1Level: LLTClassification code 10067518Term: Pancreatic neuroendocrine tumorSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 16.1Level: PTClassification code 10068909Term: Pancreatic neuroendocrine tumour metastaticSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2014-000888-41-ITFondazione IRCCS Istituto Nazionale dei tumori43
Completed
Phase 2
Efficacy and Safety of Everolimus in Patients with Unresectable or Metastatic Renal Cell Carcinomarenal cell carcinomaJPRN-UMIN000008769Tokyo Afinitor Clinical Trial Group - RCC(TACT-R)120